...
首页> 外文期刊>Molecular pharmacology. >Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract Guanine nucleotide effects on agonist binding.
【24h】

Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract Guanine nucleotide effects on agonist binding.

机译:A1腺苷受体的变构增强剂可增强受体-G蛋白偶联,并抵消鸟嘌呤核苷酸对激动剂结合的影响。

获取原文
获取原文并翻译 | 示例

摘要

Endogenous ligands of G protein-coupled receptors bind to orthosteric sites that are topologically distinct from allosteric sites. Certain aminothiophenes such as (2-amino-4,5-dimethyl-3-thienyl)-[3-(trifluromethyl)-phenyl]-methanone (PD81,723) and 2-amino-4,5,6,7-tetrahydro-benzo[b]thiophen-3-yl)-biphenyl-4-yl-methanone (ATL525) are positive allosteric regulators, or enhancers, of the human A1 adenosine receptor (A1AR). In equilibrium binding assays, 125I-N6-aminobenzyladenosine (125I-ABA) binds to two affinity states of A1AR with KD-high (0.33 microM) and KD-low ( approximately 10 nM). Enhancers have little effect on KD-high but convert all A1AR binding sites to the high-affinity state. Enhancers decrease the potency of guanosine 5'-O-(3-thio)triphosphate (GTPgammaS) as an inhibitor of agonist binding by 100-fold and increase agonist-stimulated guanine nucleotide exchange. The association of 125I-ABA to high-affinity receptors on Chinese hamster ovary (CHO)-hA1 membranes does not follow theoretical single-site association kinetics but is approximated by a bi-exponential equation with t1/2 values of 1.85 and 12.8 min. Allosteric enhancers selectively increase the number of slow binding sites, possibly by stabilizing newly formed receptor-G protein complexes. A new rapid assay method scores enhancer activity on a scale from 0 to 100 based on their ability to prevent the rapid dissociation of 125I-ABA from A1AR in response to GTPgammaS. Compared with PD81,723, ATL525 (100 microM) scores higher (27 versus 79) and has less antagonist activity. ATL525 functionally enhances A1 signaling to inhibit cAMP accumulation in CHO-hA1 cells. These data suggest that simultaneously binding orthosteric and allosteric enhancer ligands convert the A1AR from partly to fully coupled to G proteins and prevents rapid uncoupling upon binding of GTPgammaS.
机译:G蛋白偶联受体的内源性配体与拓扑上不同于变构位点的正构位点结合。某些氨基噻吩,例如(2-氨基-4,5-二甲基-3-噻吩基)-[3-(三氟甲基)-苯基]-甲酮(PD81,723)和2-氨基-4,5,6,7-四氢噻吩-苯并[b]噻吩-3-基)-联苯-4-基-甲酮(ATL525)是人A1腺苷受体(A1AR)的正变构调节剂或增强剂。在平衡结合测定中,125 I-N 6-氨基苄基腺苷(125 I-ABA)以KD高(0.33 microM)和KD低(约10 nM)结合到A1AR的两个亲和状态。增强子对高KD几乎没有影响,但会将所有A1AR结合位点转换为高亲和力状态。增强剂将鸟苷5'-O-(3-硫代)三磷酸(GTPgammaS)作为激动剂结合的抑制剂降低了100倍,并增加了激动剂刺激的鸟嘌呤核苷酸交换。 125I-ABA与中国仓鼠卵巢(CHO)-hA1膜上的高亲和力受体的缔合并不遵循理论上的单点缔合动力学,而是由t1 / 2值为1.85和12.8 min的双指数方程式近似。变构增强子可能通过稳定新形成的受体-G蛋白复合物来选择性增加慢速结合位点的数量。一种新的快速测定方法,根据增强剂防止125I-ABA响应GTPgammaS从A1AR快速解离的能力,在0到100的范围内评分。与PD81,723相比,ATL525(100 microM)得分更高(27比79),并且拮抗剂活性较低。 ATL525在功能上增强A1信号传导,以抑制cAMP在CHO-hA1细胞中的积累。这些数据表明,同时结合的正构和变构增强子配体将A1AR从G蛋白部分转化为完全偶联,并阻止了GTPgammaS结合时的快速解偶联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号